Menu
Search
|

Menu

Close
X

Eiger BioPharmaceuticals Inc EIGR.OQ (NASDAQ Stock Exchange Global Market)

8.45 USD
-0.05 (-0.59%)
As of Feb 23
chart
Previous Close 8.50
Open 8.55
Volume 12,707
3m Avg Volume 35,504
Today’s High 8.65
Today’s Low 8.40
52 Week High 16.15
52 Week Low 6.15
Shares Outstanding (mil) 8.37
Market Capitalization (mil) 107.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.17 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-3.772
FY16
-15.302
FY15
-57.968
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
5.20
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
72.07
16.52
LT Debt to Equity (MRQ)
vs sector
72.07
12.22
Return on Investment (TTM)
vs sector
-116.96
14.43
Return on Equity (TTM)
vs sector
-143.95
16.13

EXECUTIVE LEADERSHIP

David Cory
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
James Welch
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
David Apelian
Chief Operating Officer and Executive Medical Officer and Director, Since 2018
Salary: --
Bonus: --
Rebecque Laba
Vice President - Corporate Operations, Since 2015
Salary: $216,300.00
Bonus: --
Jeffrey Rudy
Vice President - Clinical Operations, Since 2006
Salary: $216,300.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

350 Cambridge Ave Ste 350
PALO ALTO   CA   94306-1577

Phone: +1650.2799845

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

SPONSORED STORIES